Morphic Therapeutic (Nasdaq: MORF) today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as the chief development officer for Loxo Oncology at Lilly.
Biotechnology company Morphic Therapeutic has formed a research and collaboration alliance with Johnson & Johnson subsidiary Janssen for the discovery and development of new integrin therapeutics....